According to incomplete statistics from Innovation Radar,Last week (9Month1To9Month7Day) Global biopharmaceutical field disclosed21Initiate transaction events, with a potential total transaction value exceeding133Billion USD, among which5A Deal Breakthrough10The $100 million mark. The transactions focus on cutting-edge technology platforms (such asLNPDelivery, covalent biologics platforms, etc.), as well as innovative therapies at various stages of development (coveringRNAi, antibody-drug conjugates, small molecule drugs, etc.).

Novartis (Novartis) InRNAiThe field continues to intensify, with two consecutive achievements last week.Blockbuster Deal。

9Month3Day,For cardiovascular diseases, Novartis and Argo BiopharmasiRNADeepening Drug Cooperation, will be granted by the latterBW-00112Priority negotiation rights for products and options for the rights outside of China for two molecules in the early research stage, treating severe hypertriglyceridemia (sHTG) and mixed dyslipidemia.Transaction Includes1.6Hundreds of millions of dollars in upfront payments, with a total potential milestone value of up to52Billion US dollars。

At the same time,Novartis andArrowhead PharmaceuticalsTargetedα-Synuclein (SNCA) ofsiRNATherapyARO-SNCAPotential Total Amount22Global Licensing Collaboration Worth US$ Billion, for the treatment of neurodegenerative diseases such as Parkinson's. Both parties will also utilizeArrowheadProprietaryTRiMThe platform is developing additional targets. It is reported that the platform has demonstrated the potential for subcutaneous injection to deliver to the central nervous system (including deep brain regions).

As multinational pharmaceutical companies actively deploy cutting-edge technologies, the R&D achievements of China's innovative pharmaceutical enterprises continue to gain international recognition. These licensing deals cover multiple disease areas, including cardiovascular, sleep disorders, and oncology.

Except for Argo's large transaction,Hengrui Pharma is in the process of3Phase clinical stageHRS-1893Exclusive rights for development, production, and commercialization granted outside of Greater ChinaBraveheart Bio`, with a potential total transaction value exceeding`10.8Billion US dollars. This is aMyosinSelective inhibitor, used for the treatment of obstructive hypertrophic cardiomyopathy (oHCM）。

Novatim Immune Therapeutics (Zhejiang) Co., Ltd. has achieved the highest11.65Hundreds of Millions of Dollars for Nanobody Bispecific AntibodiesADCMedicineKY-0301Authorized toRadiance Biopharma, this drug is expected to bring new breakthroughs in the treatment of non-small cell lung cancer, colorectal cancer, and squamous cell carcinoma of the head and neck.IrelandAvadelCompany Acquires Candidate Drug for Sleep Disorders from KarryConvaliloxybateExclusive rights for development and commercialization in the United States, Europe, and all regions except mainland China, Hong Kong, and Macao`, Potential Total Amount`2.05Hundred million dollars to strengthen its sleep product line.

In addition, the trading of innovative drug technology platforms is active. Covalent biologics platforms have gained attention:Vertex PharmaceuticalsAnnouncement withEnlaza TherapeuticsDacheng Chao20.5Multi-target Drug Discovery Collaboration Worth Hundreds of Millions of Dollars, utilizingEnlazaProprietaryWar-LockTechnical platform development of small-scale drug conjugates for certain autoimmune diseases andTCell conjugating agent, and improve sickle cell disease andβPreconditioning regimens for thalassemia patients. This platform is capable of generating highly specific warheads that can form covalent bonds with targeted drug sites.

Collaborations related to drug delivery are also a major highlight.Biocytogen and Merck KGaA (Merck KGaA) Reach Evaluation and Option Agreement, will leverage BiocytogenRenMiceThe platform's proprietary fully human antibody, co-developing antibody-conjugated lipid delivery solutions for nucleic acid drugs. Additionally,Tianze CloudTech's lipid nanoparticle delivery technology platform has also achieved multiple technical licensing collaborations.。

Readers, please star⭐Chuangjianhui to receive push notifications第一时间收到推送.

Disclaimer: This article is for information exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: Individuals are welcome to share this article on their social media circles, but unauthorized media or institutions are prohibited from reprinting or duplicating it in any form on other platforms. For reprint authorization, please contact:"InnoView"Contact us by leaving a message on our WeChat Official Account.

More Data Content Recommendations

Click "InSee", Sharing New Health Trends from Chuangjian Hui